The IDEA International Duration Evaluation of Adjuvant Chemotherapy Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX FOLFOX4 or Modified FOLFOX6 or XELOX 3Reportar como inadecuado




The IDEA International Duration Evaluation of Adjuvant Chemotherapy Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX FOLFOX4 or Modified FOLFOX6 or XELOX 3 - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Current Colorectal Cancer Reports

, Volume 9, Issue 3, pp 261–269

First Online: 23 July 2013DOI: 10.1007-s11888-013-0181-6

Cite this article as: André, T., Iveson, T., Labianca, R. et al. Curr Colorectal Cancer Rep 2013 9: 261. doi:10.1007-s11888-013-0181-6

Abstract

The International Duration Evaluation of Adjuvant Chemotherapy IDEA collaboration was established to prospectively combine and analyze data from several randomized trials conducted around the world to answer whether a three-month course of oxaliplatin-based adjuvant therapy FOLFOX4-modified FOLFOX6 or XELOX is non-inferior to the current standard six-month treatment for patients with stage III colon cancer, with a primary endpoint of three years disease-free survival. The IDEA steering committee comprises two members from each group coordinating an individual trial and two members from a secretariat who coordinate combining of the data and management of the joint analysis. Members of the IDEA agreed to combine the data from their individual trials to enable definitive analysis consisting of at least 10,500 patients. With accrual of 8,797 patients at the end of February 2013, the IDEA is on track to achieve its accrual objective of at least 10,500 patients by the end of 2013.

KeywordsColon cancer Colonic neoplasms Adjuvants pharmaceutic Stage III Chemotherapy Fluoropyrimidines 5-Fluorouracil Leucovorin Oxaliplatin Capecitabine Phase III Duration of therapy Neuropathy International collaboration IDEA Steering Committee:Timothy Iveson, M.D. and James Paul, B.Sc., Short Course Oncology Treatment SCOT trial; Cancer Clinical Trials Unit Scotland CACTUS and Oncology Clinical Trials Office OCTO groups

Roberto Labianca, M.D. and Alberto Sobrero, M.D., Three or Six Colon Adjuvant TOSCA trial; for Italian Group for the Study of Gastrointestinal Cancer GISCAD group

Thierry André, M.D., and Julien Taieb, M.D., Ph.D., IDEA France trial; for Groupe Coopérateur Multidisciplinaire en Oncologie GERCOR and Fédération Francophone de la Cancérologie Digestive, FFCD and Unicancer PRODIGE

Jeffrey A. Meyerhardt, M.D., MPH and Anthony F. Shields, M.D., Ph.D., C80702 : Celecoxib and Length of Adjuvant CLEAR colon trial trial; for Cancer and Leukemia Group B CALGB- Southwest Oncology Group SWOG trial C80702

Ioannis Souglakos, M.D., Hellenic Oncology Research Group HORG trial; for HORG Group

Atsushi Ohtsu, M.D., and Takayuki Yoshino, M.D., Adjuvant Chemotherapy for colon cancer with HIgh EVidencE ACHIEVE trial; for Japanese Foundation for Multidisciplinary Treatment of Cancer

Axel Grothey, M.D., and Daniel Sargent, Ph.D., secretariat; for North Central Cancer Treatment NCCTG Group

Download fulltext PDF



Autor: Thierry André - Timothy Iveson - Roberto Labianca - Jeffrey A. Meyerhardt - Ioannis Souglakos - Takayuki Yoshino - James 

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados